Posters

Is a touch-up procedure a negative predictor for refractive and subjective outcome?

Poster Details

First Author: M.Ezzeldin GERMANY

Co Author(s):    M. Ezzeldin   A. von Beckerath   T. Katz   A. Harfst   V. Druchkiv   A. Frings     

Abstract Details

Purpose:

To investigate the refractive results of a LASIK enhancement and its impact on treatment safety, efficacy, predictability and patient reported outcome in eyes after clear lens extraction and diffractive trifocal lens implantation.

Setting:

The data were retrieved from the Hamburg Refractive Database (Care Vision Refractive Centres in Germany).

Methods:

A retrospective cohort multicentre study of Care Vision Refractive Centres in Germany compared two groups of patients. Group 1 consisted of eyes that had non-toric MIOL surgery only, whereas group 2 had a consecutive Laser enhancement after 3 months follow-up. Refractive and subjective results of the two groups were compared. Patient reported outcome measurements were assessed by using a 30-item questionnaire with four subscales (Spectacle Dependence, Eye Comfort, Freedom and Looking/Feeling Well). Refractive results were reported following standard reporting in refractive surgery.

Results:

139 eyes of 79 patients were included in which either MIOL surgery or MIOL surgery plus LASIK enhancement had been performed between January and December 2017. UDVA reached 0.1logMAR (0.8; 20/25) in 94% in group 2 and 85% in group 1. Compared to preoperative CDVA no change in Snellen lines of CDVA was shown in 89% in group 1 and in 93% in group 2. Spectacle dependence (P= 0.41), eye comfort (P= 0.15), freedom (P=0.48) and looking/feeling well (P= 0.45) showed no statistically significant difference between both the groups.

Conclusions:

In patients with residual ametropia after MIOL implantation, LASIK provides a reliable, safe and efficient way to achieve the desired refractive outcome and patient satisfaction. We recommend performing Laser enhancement at 3 months after MIOL implantation (Bioptics) in trifocal MIOL patients that benefit from improvement of residual ametropia.

Financial Disclosure:

None